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Abstract: Mutations in DEPDC5 are causal factors for a broad spectrum of focal epilepsies, but
the underlying pathogenic mechanisms are still largely unknown. To address this
question, a zebrafish depdc5 knockout model showing spontaneous epileptiform
events in the brain, increased drug-induced seizure susceptibility, general hypoactivity
and premature death at 2-3 weeks post fertilization as well as the expected
hyperactivation of mTOR signaling was developed. Using this model, the role of
DEPDC5 in brain development was investigated using an unbiased whole
transcriptomic approach. Surprisingly, in addition to mTOR-associated genes, many
genes involved in synaptic function, neurogenesis, axonogenesis and GABA network
activity were found to be dysregulated in larval brains. Although no gross defects in
brain morphology/neuron loss were observed, immunostaining of depdc5-/- brains for
several GABAergic markers revealed specific defects in the fine branching of
GABAergic network. Consistently, some defects in depdc5-/- could be compensated by
treatment with GABA, corroborating that GABA signaling is indeed involved in
DEPDC5 pathogenicity. Further, the mTOR-independent nature of the
neurodevelopmental defects was demonstrated by the inability of rapamycin to rescue
the defects of GABAergic networks observed in depdc5-/- brains and conversely, the
inability of GABA to rescue the hypoactivity in another genetic model showing mTOR
hyperactivation. This study hence provides the first in vivo evidence that DEPDC5
plays previously unknown roles apart from its canonical function as an mTOR inhibitor.
Moreover, these results propose that defective neurodevelopment of GABAergic
network could be a key factor in epileptogenesis when DEPDC5 is mutated.
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Summary 22 
 Mutations in DEPDC5 are causal factors for a broad spectrum of focal epilepsies, but the 23 
underlying pathogenic mechanisms are still largely unknown. To address this question, a 24 
zebrafish depdc5 knockout model showing spontaneous epileptiform events in the brain, 25 
increased drug-induced seizure susceptibility, general hypoactivity, premature death at 2-3 weeks 26 
post fertilization as well as the expected hyperactivation of mTOR signaling was developed. 27 
Using this model, the role of DEPDC5 in brain development was investigated using an unbiased 28 
whole transcriptomic approach. Surprisingly, in addition to mTOR-associated genes, many genes 29 
involved in synaptic function, neurogenesis, axonogenesis and GABA network activity were 30 
found to be dysregulated in larval brains. Although no gross defects in brain morphology/neuron 31 
loss were observed, immunostaining of depdc5-/- brains for several GABAergic markers 32 
revealed specific defects in the fine branching of GABAergic network. Consistently, some 33 
defects in depdc5-/- could be compensated for by treatment with GABA, corroborating that 34 
GABA signaling is indeed involved in DEPDC5 pathogenicity. Further, the mTOR-independent 35 
nature of these neurodevelopmental defects was demonstrated by the inability of rapamycin to 36 
rescue the GABAergic network defects observed in depdc5-/- brains and conversely, the inability 37 
of GABA to rescue the hypoactivity in another genetic model showing mTOR hyperactivation. 38 
This study hence provides the first in vivo evidence that DEPDC5 plays previously unknown 39 
roles apart from its canonical function as an mTOR inhibitor. Moreover, these results propose 40 
that defective neurodevelopment of GABAergic networks could be a key factor in 41 
epileptogenesis when DEPDC5 is mutated.  42 
 43 
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Introduction: 45 
Focal seizures, which originate in one part of the brain, are the most prevalent type of 46 
epileptic seizures and mutations in DEPDC5 (Dishevelled, Egl-10 and Pleckstrin (DEP)-domain 47 
containing 5) account for 12-37% of the cases [1]. Though numerous ion channel mutations have 48 
been traditionally associated with epilepsy, recent work using whole genome/exome sequencing 49 
has identified other pathways in epilepsy, like mTOR (mechanistic/mammalian target of 50 
rapamycin) signaling. The causative gene for familial focal epilepsy with variable foci (FFEVF) 51 
remained unknown until the identification of DEPDC5 mutations in a large number of families 52 
with FFEVF [2-4]. Mutations in DEPDC5 leading to haploinsufficiency have been associated 53 
also to other focal epilepsies including autosomal dominant nocturnal frontal lobe epilepsy and 54 
familial temporal lobe epilepsy [3, 5].  55 
DEPDC5, along with NRPL2 and NRPL3 forms the mTOR inhibitory GATOR1 56 
complex, which blocks the activation of the classical mTOR complex, mTORC1, when amino 57 
acid concentration is low [6]. Mutations in all three components have been linked to focal 58 
epilepsy with/without cortical malformations [7-10]. The mTOR pathway plays a significant role 59 
in the regulation of protein synthesis and in critical cell fate decisions like autophagy. Absence of 60 
regulation of this pathway results in constitutively high mTORC1 activity, and mTOR 61 
hyperactivation has been implicated in various neurological conditions associated with 62 
intractable seizures [11]. Thus, mTOR inhibitors like rapamycin and its analogs hold significant 63 
potential in anti-epileptogenic therapies [12, 13].  64 
Since the components of the GATOR1 complex have only been recently associated with 65 
epilepsy, their pathophysiological roles related to focal epilepsy are yet to be completely 66 
understood. Moreover, some initial discoveries found that multiple DEPDC5 mutations in 67 
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patients are located in a domain of unknown function (DUF3608) [3], thus suggesting that 68 
unexpected roles of DEPDC5 may be associated with its pathogenicity. There are three rodent 69 
models of DEPDC5 knockout, where homozygotes show mTOR hyperactivation, severe 70 
morphological defects and premature death [14-16]. The conditional knockout mouse model 71 
reported recently describes cortical defects and increased seizure susceptibility in adult mice 72 
recapitulating many features of mTORopathies [16]. However, in order to investigate the 73 
function of DEPDC5 during neurodevelopment, new animal models more conducive to the study 74 
of early development are required, and hence, we used zebrafish as a handy neurodevelopmental 75 
model. 76 
In this study, we report the generation and use of a zebrafish model of DEPDC5 loss-of-77 
function to understand the underlying pathological mechanisms. This depdc5 knockout model 78 
showed mTOR hyperactivation, behavioral hypoactivity, spontaneous epileptiform brain events, 79 
increased drug-induced seizure susceptibility and premature death. An unbiased transcriptomic 80 
analysis of the brains of depdc5-/- larvae was performed which showed that, apart from the 81 
metabolic perturbation occurring due to mTOR hyperactivation, the regulation of 82 
neurodevelopmental pathways was also affected. In particular, fine branching of the GABA 83 
network was specifically affected by DEPDC5 knockout. Consistently, treatment with GABA 84 
could compensate for some of the defects. Further, these neurodevelopmental changes as well as 85 
the transcriptomic changes induced by DEPDC5 knockout occur independently of mTOR 86 
signaling. As a result, this study presents new evidence that DEPDC5 is not only involved in 87 
mTOR-dependent pathways but is also involved in previously unknown mTOR–independent 88 
functions especially during neurodevelopment, a combination of which result in focal epilepsies. 89 
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These novel insights into the function of DEPDC5 in brain development bring the first evidence 90 
of how DEPDC5 loss-of-function could lead to epilepsy.  91 
 92 
Results: 93 
 94 
Depdc5 is essential for vertebrate survival 95 
Though DEPDC5 mutations were associated with epilepsy, the underlying pathology of 96 
this class of focal epilepsies remains unstudied. Zebrafish has only one ortholog of DEPDC5, 97 
and sequence alignment of the zebrafish and human proteins showed a high degree of 98 
conservation with 75% identity and 84% similarity. Whole mount RNA in situ hybridization 99 
showed that depdc5 is expressed in the forebrain, midbrain, hindbrain and also in the neural tube 100 
and notochord during zebrafish development (Figure 1A).  101 
Using CRISPR/Cas9 genome editing, the 14th exon of depdc5 encoding the DUF3608, 102 
which was initially found to be mutated in many patients [2, 17], was targeted for disruption. A 103 
positive founder transmitting a 4-nucleotide frame-shifting deletion was selected, which would 104 
lead to the expression a truncated protein (352 amino acids instead of the 1568 residue wild-type 105 
protein, Figure 1B). Quantification of mRNA expression showed significant reduction in 106 
heterozygous and homozygous larvae (Figure 1C). Since crosses of heterozygotes never resulted 107 
in viable juvenile/adult homozygotes, according to the 1:2:1 Mendelian ratio, the survival of all 108 
the three genotypes: depdc5+/+ (wild type), depdc5+/-  and depdc5-/- was monitored for a 109 
month from 0 day post fertilization (dpf). While most of the depdc5+/+ and +/- larvae survived 110 
for this period, all the depdc5-/- larvae died by two weeks of age (Figure 1D). Notably, the 111 
survival of depdc5-/- can be extended by few days if they are separated early and raised with 112 
extra care, although they never survive after 20 dpf. However, no obvious morphological defects 113 
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or changes in eye size were observed, though a small reduction in body length was seen 114 
following quantification (Figures 1E and 1F). While this observation is consistent with the 115 
premature death of rodent Depdc5-/- models [14-16], the growth delay observed in the complete 116 
knockout rodent embryos was not evident in case of depdc5-/- zebrafish larvae. Hence, though 117 
vertebrates can survive haploinsufficiency of DEPDC5, total absence leads to death during 118 
development.  119 
 120 
depdc5-/- larvae show mTOR hyperactivation, brain epileptic discharges, hypoactivity and 121 
increased seizure susceptibility  122 
Since DEPDC5 is known to negatively regulate mTOR, mTORC1 activity was assessed 123 
through the phosphorylation state of the ribosomal protein S6, which is a downstream effector of 124 
mTORC1 [18]. Lysates of 8 dpf depdc5+/+, depdc5+/- and depdc5-/- larvae were analyzed by 125 
western blotting using antibodies against the S6 Ser240/244 phospho-epitope, and a gradual 126 
increase in the phosphorylation was observed (Figure 2A), indicating high mTORC1 activity in 127 
the absence of DEPDC5. This was confirmed by performing immunohistological analysis where 128 
depdc5-/- larval brains showed greater levels of phospho-S6 (Figure 2B). However, no abnormal 129 
or dysmorphic cells were visible. In order to monitor epileptic activity, brain activity was 130 
monitored using non-invasive local field potential (LFP) recordings from the optic tectum [19]. 131 
Recurrent spontaneous epileptiform events were observed in depdc5-/- larval brains at 9 dpf 132 
(Figures 2C and 2D) at a mean frequency of 9.1 + 5.0 events/10 minutes and mean duration of 133 
309.7 + 152.3 msec, confirming the pathogenicity of DEPDC5 loss-of-function. However, since 134 
the LFPs were monitored only for 10 minutes, this epileptic brain activity was observed in only 135 
9/42 larvae, and it is possible that many larvae show epileptiform discharges outside this period. 136 
Nevertheless, no such events were recorded in different batches of depdc5+/+ (0 out of 40 137 
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larvae). It is also possible that these epileptiform discharges manifest earlier but were only 138 
monitored at 9 dpf in order to increase the chances of detecting them. The absence of 139 
epileptiform discharges in 100% of the animals is consistent with similar observations in Depdc5 140 
conditional knockout mice and patients with focal epilepsy [16]. In order to have a more accurate 141 
readout of the abnormalities in depdc5-/- larvae, their locomotor activity was quantified in light-142 
dark cycles. depdc5-/- larvae were significantly hypoactive (Figure 2E), and this was observed in 143 
100% of the larvae across generations from 5 dpf onward (N>5; n>300), till before death. These 144 
results are also consistent with other mTORopathy zebrafish models which show epileptic brain 145 
activity and are hypoactive [20]. Interestingly, when coiling (rotating movement of embryo 146 
inside the chorion) was monitored at 20 hpf, this earliest motor behavior was already lower in 147 
depdc5-/- embryos (Figure 2F), indicating that the hypoactivity begins very early during 148 
development, suggesting that DEPDC5 loss-of-function may have consequences on early 149 
neurodevelopment. Lastly, the susceptibility of depdc5-/- larvae to chemically-induced seizures 150 
by pentylenetetrazol (PTZ) was tested. Consistently with what have been reported in mice [16], 151 
depdc5-/- larvae show a significantly increased response to PTZ (shorter delay of response to 152 
PTZ exposure and higher swimming activity) compared to their siblings (Figure 2G and 2H).  153 
Altogether, the phenotypes observed upon knocking out depdc5 in zebrafish are 154 
reminiscent of what is observed in the existing rodent models of Depdc5 knockout and also to an 155 
extent, in patients. Altogether, these results validate the pathogenicity of depdc5 loss-of-function 156 
in zebrafish.  157 
 158 
Alteration of brain gene expression profile in depdc5-/-  159 
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 In order to obtain new unbiased insights into the molecular perturbations occurring 160 
during neurodevelopment in the absence of DEPDC5, brains of 10 dpf depdc5+/+ and -/- larvae 161 
were dissected out and total RNA was extracted for deep sequencing (Figure 3A). This age was 162 
chosen as an intermediate stage to perform exhaustive analysis of the molecular phenotype at a 163 
stage when the swimming phenotype is distinct, while preventing the perturbation of gene 164 
expression by the premature death that occurs 5 days later.  From the differential gene expression 165 
analysis, 1191 genes out of approximately 12,000 genes expressed in the larval brain were found 166 
to be significantly up- (532 genes) or downregulated (659 genes) (p<0.05) (full list can be found 167 
in Table S1, description provided for top dysregulated genes). Notably, 16 out of the 20 168 
aminoacyl-tRNA synthetases in zebrafish were upregulated in the depdc5-/- brains, presumably 169 
due to improper mTOR regulation. Functional annotation and clustering of the significantly 170 
dysregulated genes showed that apart from aminoacyl-tRNA biosynthesis and electron transport 171 
chain that can be attributed to mTOR pathway dysfunction, the expression of genes involved in 172 
other pathways including chordate embryonic pattern specification, regulation of neuron 173 
projection morphogenesis/axonogenesis, synapse formation, zinc finger/transcription factors and 174 
ion channels were also perturbed (Figure 3B). This suggested that DEPDC5 may also play a role 175 
in embryonic neurodevelopment.  176 
 Since genes related to neurodevelopment were altered, the number of neurons during 177 
developmental stages was analyzed. Measurement of the head size and staining with cresyl violet 178 
showed that the size and morphology of depdc5-/- larval brains were similar to that of the control 179 
(Figures 3D and 3F). In addition, using immunostaining against acetylated tubulin and 180 
phosphorylated histone H3 (which label neuronal fibres and mitotic cells respectively), the main 181 
brain networks and neurogenesis itself did not appear to be affected (Figures 3C and 3E).  182 
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However, many genes related to GABAergic networks which have conventionally been 183 
correlated with other kinds of epilepsy, were downregulated. Indeed, 3 GABA receptors 184 
(GABRA1, GABBR1b and GABRG2) and other associated factors required for synthesis and 185 
transport of GABA, GABAergic synapse formation, maturation and transmission (like Gat3, 186 
pyruvate carboxylase, Kcc2 and neuroligin 2) were all downregulated (Table S3).   187 
Since the expression of multiple factors important for GABAergic network formation and 188 
synaptic function was perturbed, the expression of three markers of inhibitory synapses, 189 
Gad65/67, gephyrin and neurogilin-2 (Nlgn-2), was examined by immunostaining of transverse 190 
sections from 8 dpf depdc5+/+ and depdc5-/- larval brains. Interestingly, close examination of 191 
the sections immunostained with Gad65/67 showed that finer branched structures were not 192 
present as in wild type siblings (Figure 4A). 3D reconstruction of Gad65/67 staining confirmed 193 
that the Gad65/67 projections (in blue in Figure 4B) are less arborized in the mutant brains. 194 
Since GABA synthetizing enzymes are expressed in clusters at the pre-synaptic GABA synapses, 195 
these results confirm defects in the GABAergic network connectivity. Immunolabeling against 196 
gephyrin and Nlgn2 also showed a significant decrease of the complexity in depdc5-/- brains 197 
(Figures 4C and 4D). Upon quantifying the GAD65/67 and gephyrin positive neurofilaments and 198 
puncta from at least three biological replicates, both were decreased by >50% in depdc5-/- 199 
(Figure 4F). Lastly, immunolabelling and quantification of the interneuron population using 200 
parvalbumin 7 antibody did not show any difference in the number of positive cells (Figure 4E 201 
and 4F). These results demonstrate that DEPDC5 loss-of-function significantly impacts fine 202 
branching of GABAergic network during neurodevelopment without causing major loss of 203 
interneurons.   204 
 205 
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GABA exposure rescues hypoactivity and seizure susceptibility in depdc5-/- larvae through 206 
paracrine effects 207 
Since the expression of GABA synthetizing enzymes seemed to be affected, we 208 
hypothesized that exposure to GABA may compensate for this decrease and could therefore 209 
rescue the consistent hypoactivity and seizure susceptibility phenotypes of depdc5-/- larvae. 210 
Concurrently with this hypothesis, GABA treatment could completely rescue the hypoactivity of 211 
depdc5-/- larvae (swimming at 7 dpf and coiling at 24 hpf) (Figures 5A and 5B). Rapamycin, 212 
which has a positive effect on other mTORopathy models, was used as a positive control, and 213 
could also completely rescue the hypoactivity of depdc5-/- embryos and the increased phospho-214 
S6 levels (Figures 5A-C). Moreover, GABA treatment, as well as rapamycin could rescue the 215 
seizure susceptibility of depdc5-/- larvae exposed to PTZ, to the level of their siblings (Figures 216 
5D and 5E). Hence, these results confirm earlier observations from transcriptomic and 217 
immunolabelling experiments that GABA network/signalling is indeed altered in depdc5-/- 218 
larvae. Moreover, it shows that both GABA and mTOR signalling are involved in the 219 
pathogenicity of depdc5 loss-of-function. 220 
In order to assess if this rescuing effect could be a result of a rescue of the 221 
neurodevelopmental defects themselves, neuronal branching of GABAergic neurons was 222 
monitored following GABA treatment. However, supplementation with GABA could not rescue 223 
the fine neuronal branching defects observed in depdc5-/- larvae (Figures 5F and 5G) thus 224 
suggesting that GABA can only compensate for, but not rescue the neurodevelopmental defects. 225 
Further, when the effect of GABA and rapamycin treatment on larval survival was tested, GABA 226 
exposure could not rescue the premature death at 2-3 weeks post fertilization (wpf), while 227 
rapamycin treatment extended the life span as long as it was supplemented (Figure 5H). This 228 
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supports our conclusion that GABA exposure can only partially compensate for the 229 
neurodevelopmental defects. 230 
Hence, these results show that while increasing GABA levels could compensate for 231 
defective GABAergic branching, it could not rescue the neurodevelopmental defect itself. This 232 
also indicates that the premature death is essentially due to perturbation of mTOR signaling 233 
(which could be rescued by rapamycin), rather than the GABA network defects. Indeed, 234 
rapamycin needed to be continually supplemented, since withdrawal of rapamycin led to gradual 235 
death (Figure 5H), reiterating the contribution of mTOR deregulation to premature death.  236 
In order to understand if the compensating effect of GABA was mediated through GABA 237 
receptors or independently of them, muscimol (a GABAA receptor agonist), baclofen (a GABAB 238 
receptor agonist) and vigabatrin (an inhibitor of GABA transaminase which increases local 239 
GABA concentration) were tested for their effect on depdc5-/- larvae (Figure 6A). Interestingly, 240 
treatment with the GABA receptor agonists, muscimol, baclofen, and even both in combination 241 
could not rescue the hypoactivity. However, exposure to vigabatrin, which increases endogenous 242 
GABA level by inhibiting its metabolism, completely rescued the hypoactivity of depdc5-/- 243 
larvae as well as PTZ hypersensitivity (Figure 6B). This proves that GABA acts through 244 
receptor-independent mechanisms in a paracrine fashion. Moreover, the fact that inhibiting 245 
GABA metabolism using vigabatrin is sufficient to rescue the phenotype suggests that GABA 246 
itself mediates the compensating effects rather than metabolites of GABA.  247 
Altogether these results support the idea that DEPDC5 loss-of-function impairs early 248 
neurodevelopment especially GABA network fine branching which is likely to contribute to 249 
epileptogenesis, and that mTOR-dependent metabolic changes are more generalized and severe, 250 
eventually resulting in premature death.  251 
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 252 
mTOR-dependent and independent pathways are perturbed in depdc5-/- larvae  253 
In order to further understand whether these two phenomena: upregulation of mTOR 254 
signaling, and defective development of GABAergic networks are related and act together in the 255 
same pathway, or are controlled independently by DEPDC5, the depdc5-/- differentially 256 
expressed gene dataset was compared to datasets from three other zebrafish models of epilepsy. 257 
These included: (1) a gabra1-/- zebrafish line recapitulating idiopathic generalized epilepsy, in 258 
which GABAergic network is defective (Samarut et al., under review) (2) an mTORopathy 259 
epilepsy (tsc2-/-) zebrafish model in which mTORC1 activity is increased [20], and (3) a Dravet 260 
syndrome zebrafish model (scn1Lab mutant carrying a mutation in Nav1.1 [21]), as a neutral 261 
mTOR- and GABA-non-related epilepsy model (Figure 6C).  262 
177 genes were found to overlap between the depdc5 and gabra1 datasets (15% and 40% 263 
of the total number of genes in the depdc5 and gabra1 datasets respectively), and remarkably, 264 
99% of them (175/177) showed the same trend of up- or downregulation in both datasets 265 
suggesting specific common mechanisms. When functional clustering and annotation of the 266 
common genes was performed, these genes were found to be involved in electron transport, 267 
embryonic morphogenesis, GABA receptor activity, synapse formation, general synaptic 268 
activity, axonogenesis, nucleotide binding and transcription (Figure 6D and Table S3). 269 
Interestingly, many factors which have been associated with epilepsy earlier were also 270 
dysregulated. This significant overlap between depdc5 and gabra1 datasets provides further 271 
evidence that DEPDC5 loss-of-function induces broad defects in GABA network. 272 
Since both DEPDC5 and TSC2 are involved in the negative regulation of mTOR, 273 
common genes between these two datasets showed mTOR-related pathways as the largest group 274 
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of genes, upon functional clustering and annotation (Table S4). About 15% genes of the two 275 
datasets were found to be genes encoding for mTOR related members like aminoacyl-tRNA 276 
synthetases, stress response and protein phosphorylation. The overlap of the depdc5 dataset with 277 
data from other models of epilepsy (Scn1Lab) and autism spectrum disorder (unpublished, data 278 
not shown) did not show a significant overlap (only 23 genes in common between depdc5-/- and 279 
Scn1Lab-/- datasets) thus confirming the specificity of the overlaps described above. 280 
Surprisingly, among the 177 common genes between the gabra1 and depdc5 datasets 281 
which were involved in neurogenesis and GABA networks, only 18 genes were found to be 282 
common with the tsc2 dataset. The non-overlapping nature of 90% (159 of 177) of the genes 283 
indicates that these neurodevelopment-associated genes are more likely to be unrelated to 284 
mTOR, but rather controlled by DEPDC5 independently of its canonical mTOR-inhibitory 285 
function. These observations show that in the absence of DEPDC5, there are mTOR-dependent 286 
metabolic changes (which overlap with the tsc2 model) but also mTOR-independent 287 
neurodevelopment defects especially in the GABAergic network (which overlap with the gabra1 288 
model), a combination of which presumably leads to epilepsy.  289 
 290 
Neurodevelopmental defects in depdc5-/- larvae are independent of mTOR signaling       291 
In order to confirm the independent nature of the mTOR and GABA pathways, mTOR 292 
signaling was assessed following treatment with GABA in depdc5+/+ and -/- larvae (Figure 293 
7A). Consistent with the hypothesis, GABA treatment could not rescue the increase in mTOR 294 
activity in depdc5-/- larvae (Figure 7A, upper panel).  Moreover, the levels of phospho-S6 were 295 
also checked in gabra1-/- larvae, which have defective GABA signaling and it did not show any 296 
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change (Figure 7A lower panel). These results indicate that GABA and its related metabolism do 297 
not control mTOR signaling.  298 
Further, in order to confirm that the neurodevelopmental defects induced by depdc5 loss-299 
of-function are indeed mTOR-independent, the ability of rapamycin to rescue the fine branching 300 
of the GABAergic network in depdc5-/- larval brains was assessed. Brain slices from rapamycin 301 
treated depdc5+/+ and -/- larvae were immunostained using -GAD65/67. Rapamycin treatment 302 
failed to rescue the reduced fine branching of the GABAergic network during development in 303 
depdc5-/-.  Indeed, similar to what was observed in untreated depdc5-/- brains (Figure 4), the 304 
GAD65/67-positive neurofilaments were less arborized even after rapamycin treatment (Figure 305 
7B and 7C), proving that the GABAergic branching defects resulting from the absence of 306 
DEPDC5 are indeed mTOR-independent. Of note, phospho-S6 levels are significantly reduced 307 
when rapamycin was applied at this concentration (Figure 7D).  308 
To confirm the mTOR-independent effects at the molecular level, the ability of 309 
rapamycin to restore the expression of critical up- and downregulated genes back to normal was 310 
tested in order to assess if the transcriptional changes were also mTOR independent. The genes 311 
that were chosen for testing by RT-qPCR were related to axon guidance (plxn2a, sema3b, 312 
efnb3b) and GABA synapse (gabrg2, gat3, kcc2), which were in common with the gabra1 313 
dataset, and also some mitochondrial factors (mt-cyb, mt-co2). Consistently with their 314 
involvement in metabolic processes, the expression of mitochondrial cytochrome B and 315 
cytochrome C oxidase II genes in depdc5-/- brains was decreased to wild-type level upon 316 
rapamycin treatment (Figure 7E). However, for the genes involved in axon guidance and GABA 317 
synapse activity, rapamycin treatment could not rescue the reduced expression observed in 318 
depdc5-/- larval brains (Figure 7E). This incapability of rapamycin to rescue both, the 319 
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neurodevelopmental defects and the transcriptional changes proves that the molecular defects are 320 
indeed mTOR-independent.  321 
Lastly, if GABAergic network defects induced by DEPDC5 knockout are mTOR 322 
independent, GABA would not have any effect on another genetic model of mTOR 323 
hyperactivation such as tsc2-/- [20]. Consistently, when tested on tsc2-/- larvae, GABA was 324 
unable to rescue the hypoactivity, again validating the mTOR-independent nature of the defects 325 
observed in depdc5-/- larvae (Figure 7F). Of note, rapamycin, which was used as a positive 326 
control could rescue the hypoactivity observed in tsc2-/- larvae.  327 
Hence, these results show that at the phenotypic, cellular and molecular levels, alongside 328 
its canonical mTOR inhibitory function, DEPDC5 does control neurodevelopmental aspects of 329 
GABAergic networks in an mTOR independent fashion. 330 
 331 
Discussion: 332 
Mutations in the members of the mTOR-inhibitory GATOR1 complex have recently been 333 
shown to be associated with focal epilepsy [7-10]. However, multiple aspects of this complex 334 
remain poorly understood, including the molecular pathways through which it plays a role in 335 
normal brain activity and/or development.  336 
Depdc5 is strongly expressed in the developing vertebrate nervous system as shown by in 337 
situ hybridization of early zebrafish embryos, indicating a role for this protein in neuronal 338 
development. DEPDC5 is expressed specifically in neurons in the human brain (Human protein 339 
atlas database and Human brain transcriptome project) where the transcript was first identified 340 
[2, 22], but this is the first report showing its strong expression in the developing vertebrate 341 
neural system. 342 
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In order to understand the role of DEPDC5 in neurodevelopment and brain activity, the 343 
first zebrafish knockout model of depdc5 was generated and studied. Although rodent models 344 
have been recently generated [14-16], the zebrafish model proffers specific technical advantages 345 
for studying early neurodevelopment. Though depdc5-/- zebrafish larvae do not show obvious 346 
phenotypic changes, they exhibit transient spontaneous epileptiform discharges in their brain and 347 
increased seizure susceptibility before they die prematurely at about 2 wpf. The zebrafish model 348 
also proffers a platform for drug screening purposes. Our zebrafish model would be convenient 349 
for initial high-throughput drug screening assays that could identify candidate molecules 350 
restoring depdc5-/- larval phenotype (i.e. hypoactivity and seizure susceptibility) and later be 351 
confirmed in mammalian models. Such an approach using complementary vertebrate models has 352 
proven to be effective and time-saving in identifying new therapeutics for other genetic diseases 353 
[23]. 354 
Hypoactivity and seizure susceptibility of the larvae was consistently observed and could 355 
be used as an accurate readout for further studies. It is noteworthy that another zebrafish model 356 
with hyperactive mTOR owing to mutated tsc2 also shows hypoactivity and premature death 357 
along with epileptic seizures [20]. Also, since the hypoactivity is observed from very early on, 358 
coiling could also be used as a readout in drug screening to economize on time. Notably, no 359 
enlarged or abnormal cells were detected in the developing zebrafish brains in this model. This 360 
could be explained by the “two-hit” hypothesis where an additional hit along with DEPDC5 361 
mutations occurs to cause FCD in patients [9]. Also, though depdc5-/- larvae show considerably 362 
less mRNA levels, it was not completely absent, probably due to incomplete degradation of 363 
depdc5 mRNA by nonsense-mediated decay. However, the significant reduction of mRNA levels 364 
show that the phenotypes observed were a result of haploinsufficiency.  365 
 17 
With the aim to get further insights into the molecular perturbations in the epileptic 366 
depdc5-/- brains, transcriptomic analysis was performed in this study, which showed interesting 367 
candidates that were up- or downregulated. This is the first report of an in vivo transcriptomic 368 
profile from a model of dysfunctional GATOR1 complex. As expected, various mTOR-regulated 369 
pathways like amino acid metabolism were upregulated owing to mTOR deregulation, including 370 
most amino acyl tRNA synthetases. While loss-of-function mutations in some aminoacyl-tRNA 371 
synthetases have been shown to be associated with epilepsy [24-27], the contribution of such a 372 
broad upregulation in expression levels of these factors to epilepsy remains to be understood.  373 
Interestingly, though factors associated with neurogenesis, axonogenesis and synaptic 374 
functions were downregulated, rather than gross morphological defect or neuron loss, specific 375 
downregulation of GABA receptors, transporters and factors involved in inhibitory network 376 
development, synapse formation and function was observed, revealing for the first time the 377 
possible role of DEPDC5 in the formation, pruning and maintenance of the GABAergic system.  378 
GABA exposure could partially compensate the phenotype observed in depdc5-/- larvae. 379 
The use of GABA receptor agonists in mTORopathies has been explored only for TSC [28], but 380 
muscimol and baclofen were ineffective in depdc5-/- larvae. These observations suggest that the 381 
compensating effect of GABA is more likely to be a paracrine effect of GABA rather than 382 
through GABA receptors. In this context, the ability of vigabatrin to rescue the phenotype also 383 
confirms the direct effect of GABA rather than of its metabolites. Notably, GABA can only 384 
partially ameliorate the depdc5-/- phenotype and therefore cannot be considered as a candidate 385 
drug against refractory epilepsies. However, the observation that GABAergic networks are 386 
affected early during development in a vertebrate DEPDC5 knockout model is an important 387 
consideration for treatment strategies. Indeed, it might be useful to design therapeutic strategies 388 
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that can restore or at least compensate stably, the neurodevelopmental defects, rather than solely 389 
trying to treat symptomatically, i.e., alleviate the seizures. Notably, the paracrine effect of 390 
GABA observed here is also significant since many patients with mutations in DEPDC5 are 391 
refractory to conventional anti-epileptic drugs, which generally act through GABA receptors 392 
such as benzodiazepines. Thus, the application of molecules that would increase GABA 393 
signaling independently of GABA receptors (such as vigabatrin) could be interesting in the 394 
context of these refractory epilepsies. 395 
Predictably, rapamycin could rescue the phenotype, and also prevent premature death, 396 
suggesting that mTOR deregulation affects multiple organismal functions. Rapamycin and 397 
rapalogs have proved to be extremely effective against many mTOR associated diseases 398 
including cancer, lymphangioleiomyomatosis (LAM) and tuberous sclerosis [29-31]. Rapamycin 399 
has also been shown to extend longevity and have neuroprotective effects [32, 33]. Like in 400 
earlier studies with other diseases, though very effective, cessation of rapamycin treatment led to 401 
reappearance of the symptoms and death [30, 34]. Due to various reasons including activation of 402 
alternate or compensatory pathways, rapamycin treatment has had modest outcomes in clinical 403 
trials despite very promising pre-clinical animal model studies [35]. Hence, rapamycin and 404 
rapalogs are now being tested for combination therapy as chemotherapeutic agents, and these 405 
could also be applied to treat focal epilepsies, since there is a need to identify new targetable 406 
mechanisms of focal epilepsy in order to design new drugs against refractory seizures.  407 
Through multiple comparison of transcriptomic datasets, a large set of genes from the 408 
depdc5 dataset was found to overlap with the gabra1 dataset independently of the tsc2 dataset, 409 
suggesting that DEPDC5 has unexpected mTOR-independent activity, especially in regulating 410 
GABA network development, as proven experimentally (Figure 7). Hence, it is possible that the 411 
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two inhibitory complexes, GATOR1 (via DEPDC5) and TSC play distinct roles in different 412 
pathways and cell types in addition to their overlapping mTOR-related functions. DEPDC5 413 
function is still incompletely understood and many epileptic mutations have been identified in 414 
different domains of DEPDC5 including DUF3608 [2, 3], which also supports the idea that there 415 
could be other yet undiscovered functions of DEPDC5. Though mTOR activity has been 416 
associated with proper neuronal development [36-38], this study shows that the 417 
neurodevelopmental role of DEPDC5 is mTOR-independent. Hence, in addition to controlling 418 
neuronal development through mTOR, the components of the pathway might also have mTOR-419 
independent roles.  420 
Altogether, these results show a novel mTOR-independent effect of DEPDC5 on the 421 
GABAergic network that is very likely to be a key component of DEPDC5-mediated focal 422 
epilepsy substratum. Indeed, abnormal wiring and functioning of the GABAergic system have 423 
been observed in epilepsy [39] and GABA agonists have been used for decades alongside other 424 
drugs like sodium and calcium channel blockers, glutamate blockers, carbonic anhydrase 425 
inhibitors, and other drugs as anti-epileptics [40, 41]. Since GABA is the primary inhibitory 426 
neurotransmitter in the cortex, GABA agonists have long been considered the logical choice as 427 
anti-epileptic agents. However, in the emerging field of epilepsies caused by mutations in non-428 
ion channel genes, the contribution of the GABAergic network to epilepsy has not been studied 429 
and this study shows that modulation of the GABAergic network together with targeting mTOR 430 
could be very effective against this class of non-ion channelopathies.  431 
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Figure legends: 594 
Figure 1: depdc5 is essential for survival. (A) Whole mount in situ hybridization showing 595 
expression of depdc5 at different stages of development. (B) Electropherograms showing 596 
confirmation of the 4 bp insertion by Sanger sequencing. (C) Expression of depdc5 transcript in 597 
7 dpf depdc5+/+, +/- and -/- larvae (N=3, Student’s t test: p (WT vs HT)=0.0026; p (WT vs 598 
HM)=0.001). (D) Survival curve showing that depdc5-/- embryos have reduced survival with 599 
most larvae dying around 14 dpf (N=2, n=15 per genotype). (E) Images showing that depdc5-/- 600 
larvae don’t show gross morphological changes at 3 dpf. (F) Measurement of body length (upper 601 
panel; n=20/genotype; p=0.0045 by unpaired Student’s t-test) and eye size (lower panel; 602 
n=12/genotype; p=0.7219 by unpaired Student’s t-test) showed no significant change in either 603 
parameter.  604 
 605 
Figure 2: depdc5 knockout results in increased mTOR activity, hypoactivity, epileptiform 606 
discharges and seizure susceptibility. (A) Western blotting of 7 dpf larval lysates to examine 607 
phospho-S6 levels in depdc5+/+, depdc5+/- and depdc5-/- larvae showing hyperactivation of 608 
mTOR signalling. (n=3; p(WTvsHT) = 0.0012; p(WTvsHM) = 0.0455). (B) Images of 6 dpf 609 
depdc5+/+ and depdc5-/- larval brains (transversal sections across the optic tectum) 610 
immunostained with phospho-S6 antibodies and counterstained with DAPI. The panels on the 611 
extreme right depict 3D reconstruction of single cells in depdc5+/+ and -/- brains (Scale bars 612 
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from left to right panels: 20µm, 2.5µm, 1.5µm). (C) Spontaneous extracellular electrographic 613 
activity recorded from the optic tectum of depdc5+/+ or depdc5-/- larvae at 9 dpf showing 614 
representative epileptiform activity of depdc5-/- larvae displaying polyspiking discharges. (D) 615 
Percentage of depdc5+/+ and depdc5-/- larvae showing epileptiform activity in the brain (N=4; 616 
n=10/genotype, Student’s t-test p(WTvs HM)<0.0001). (E) Distance swam by 8 dpf larvae 617 
across two 2 hour dark-4 hour light cycles. (F) Spontaneous coiling activity in 20 hpf embryos 618 
monitored over 20 minutes represented as the percentage of total time during which the embryos 619 
were active (N=3, n=20, Student’s t-test p (WT vs HM)<0.0001). (G) Distance swam by 2 dpf 620 
embryos upon exposure to 3mM PTZ represented as fold change compared to basal distance 621 
swam by wildtype larvae at t0. (N=3, n>10, student t-test, *: p<0.05) (H) Representative 622 
swimming tracks of 2 dpf embryos during a 10-minute period following a 3mM PTZ exposure 623 
(tracks of 3 replicates are shown in rows for each genotype). 624 
 625 
Figure 3: depdc5 knockout alters gene expression in larval brains without affecting brain 626 
morphology (A) Volcano plot showing the differentially expressed gene expression profile 627 
between depdc5+/+ and depdc5-/- larval brains. See also Table S1. (B) Pathways showing high 628 
enrichment in the differentially expressed genes (upregulated are shown in green, 629 
downregulated, in red). (C) Whole mount images of depdc5+/+ and -/- larvae at different stages 630 
of development immunostained with -acetylated tubulin. (n>3/genotype/developmental stage; 631 
Scale bar:40 m).(D) Measurement of head size and head surface area in 3 dpf depdc5+/+ and 632 
depdc5-/- larvae. (E) Whole mount images of 48 hpf depdc5+/+ and -/- larvae immunostained 633 
with -phosphorylated histone H3 (n>3/genotype). (F) Cresyl violet staining comparing 7 dpf 634 
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depdc5+/+ (top half) and depdc5-/- (bottom half) larval heads showed no gross difference in the 635 
density of cells in the brain. Scale bar=100 m. 636 
 637 
Figure 4: Defects in GABAergic networks in depdc5 knockout zebrafish brains.  Images of 638 
transverse sections of 6 dpf depdc5+/+ and depdc5-/- embryos immunostained with GAD65/67 639 
(A), gephyrin (C) and Nlgn2 (D) antibodies and counterstained with DAPI. Section level is 640 
displayed in the schematic drawing. Regions indicated in red boxes have been magnified to show 641 
the branching defects (N=3, n=3 embryos/genotype). Scale bar: 10 m. (B) Imaris-reconstructed 642 
3D image with Gad65/67 positive GABAergic boutons shown in green projecting towards the 643 
nucleus (DAPI) shown in blue. (Scale bar=2 µm). (E) Images of longitudinal sections of 6 dpf 644 
depdc5+/+ and depdc5-/- embryos immunostained with parvalbumin 7 antibody (Scale 645 
bar=25µm). Field of view is displayed in the schematic drawing (F) Quantification of the number 646 
of GAD65/67-positive neurofilaments, gephyrin-positive puncta and parvalbumin-positive cells 647 
in depdc5+/+ and -/- larval brain sections (N=3, n>3 embryos/genotype).  648 
 649 
Figure 5: Rescuing effect of GABA and rapamycin on depdc5 knockout zebrafish. (A) 650 
Swimming activity of 8 dpf larvae, with the activity of depdc5 +/+ larvae normalized to 100% 651 
shows that treatment with GABA (100 M) can completely rescue hypoactivity (N=2, 652 
n=20/genotype/treatment). Rapamycin treatment (100 nM from day 0-2, 300 nM from day 3 653 
onwards) was used as a positive control. (B) Spontaneous coiling activity in 20 hpf embryos 654 
shows that the hypoactivity of depdc5-/- embryos is rescued by treating with 100 nM rapamycin 655 
or with 100 M GABA from single-cell stage (N=2, n=20/genotype/treatment, Student’s t-test p 656 
(Control WT vs HM) <0.0001:****). Coiling activity of depdc5+/+ was set at 100% for each 657 
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sample, and the relative activity of the depdc5-/- larvae is represented. (C) Western blotting of 9 658 
dpf larval lysates to examine phospho-S6 levels in depdc5+/+ and depdc5-/- larvae treated with 659 
DMSO or rapamycin (100 nM from day 0-2, 300 nM from day 3 onwards) shows inhibition of 660 
mTOR signaling upon rapamycin treatment. (D) Distance swam by 2 dpf larvae treated with 661 
GABA (100µM) or rapamycin (100nM) upon PTZ exposure (3mM) (N=3, n>10). (E) 662 
Representative swimming tracks of 2 dpf embryos (untreated or treated with GABA or 663 
rapamycin) during a 10-minute period following PTZ exposure (3mM). (F) Images of transverse 664 
sections of 7 dpf GABA treated depdc5+/+ and depc5-/- larval brains immunostained with -665 
GAD65/67 and counterstained with DAPI. Regions indicated in red boxes have been magnified 666 
to show the branching defects. GABA treatment (100 M) was begun at 8 hpf (n=3 667 
embryos/genotype). (G) Quantification of the number of GAD65/67 positive neurofilaments in 668 
GABA-treated depdc5+/+ and -/- larval brain sections showing that GABA treatment does not 669 
rescue the defects in depdc5-/-. (H) Survival curve showing that treatment of depdc5-/- larvae 670 
with rapamycin (100 nM from day 0-2, 300 nM from day 3 onwards) first prolongs lifespan as 671 
long as rapamycin is supplemented to the water (till day 20-shaded). Withdrawal of rapamycin 672 
results in a drop in survival and all the larvae die by day 35. On the contrary, treatment with 100 673 
M GABA from 8 hpf doesn’t extend survival. Both rapamycin and GABA did not affect 674 
depdc5+/+.  675 
 676 
Figure 6: Paracrine compensation by GABA and modulation of multiple independent 677 
pathways in depdc5 knockout zebrafish. (A) Swimming activity of 8 dpf larvae treated with 678 
muscimol (100 M), baclofen (100 M), a combination of both or vigabatrin (5 mM) with the 679 
activity of depdc5+/+ larvae normalized to 100% shows that treatment with vigabatrin can 680 
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completely rescue hypoactivity, while GABA receptor agonists cannot. (B) Vigabatrin treatment 681 
completely rescues PTZ-hypersensitivity of 2 dpf depdc5-/- embryos (N=2, n>30; student t-test, 682 
*: p value <0.05). (C) Overlap between gene expression datasets from depdc5, gabra1, tsc2 and 683 
scn1a mutants. See also Tables S2 and S4. (D) A representation of the common pathways (axon 684 
guidance and GABA synapse) affected in depdc5 and gabra1 knockout brains with the common 685 
genes indicated. See also Table S3. 686 
 687 
Figure 7: mTOR deregulation and GABAergic defects are independent effects of Depdc5 688 
knockout. (A) Western blotting of 7 dpf depdc5+/+ and depdc5-/- larval lysates shows no 689 
change in phospho-S6 levels upon GABA treatment (100 M from 8 hpf; top panel). Western 690 
blotting of 7 dpf gabra1+/+ and gabra1-/- larval lysates shows no difference in mTOR signaling 691 
upon knocking out gabra1 (bottom panel). (B) Images of transverse sections of 7 dpf rapamycin 692 
treated depdc5+/+ and depc5-/- larvae immunostained with -GAD65/67 and counterstained 693 
with DAPI. Section level is displayed in the schematic drawing. Regions indicated in red boxes 694 
have been magnified to show the branching defects. Rapamycin treatment was begun at 8 hpf: 695 
100 nM from day 0-2, 300 nM from day 3 onwards (n=3/genotype). Scale bar=10 m. (C) 696 
Quantification of GAD65/67 positive neurofilaments in rapamycin treated depdc5+/+ and -/- 697 
larval brain sections shows that rapamycin treatment does not rescue the reduced number of 698 
filaments in depdc5-/-. (D) Western blotting of 5 dpf larval lysates upon treatment with 699 
increasing concentrations of rapamycin (50 nM, 250 nM, 500 nM, 1 M and 2.5 M) from 8 hpf 700 
to estimate phospho-S6 levels shows a dose-dependent decrease. Rapamycin-containing water 701 
was changed everyday. (E) qRT-PCR based estimation of some down- and upregulated genes 702 
involved in axon guidance, GABA synapse and metabolism. ef1a expression was used for 703 
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normalization, expression of depdc5+/+ was normalized to 1.  (p<0.05:*; p<0.01:**). (F) 704 
Swimming activity of 7 dpf tsc2 larvae treated with rapamycin and GABA (day 0 onwards) over 705 
5 minute light-10 minute dark phases, with the activity of tsc2+/+ larvae normalized to 100% 706 
shows that rapamycin, but not GABA can rescue the hypoactivity (Student’s t-test 707 
p<0.0001:****). 708 
 709 
 710 
STAR methods: 711 
Contact for reagent and resource sharing 712 
Further information and requests for resources and reagents should be directed to and will be 713 
fulfilled by the Lead contact: Éric Samarut (eric.samarut@umontreal.ca) 714 
 715 
Experimental model and subject details 716 
Routine zebrafish (Danio rerio) maintenance was performed following standard procedures 717 
(Westerfield) at 28.50C under 12/12 hour light/dark cycles at the animal facility of the Centre 718 
Hospitalier de l’Université de Montréal Research Centre (CRCHUM), Montréal. All experiments 719 
were performed in compliance with the guidelines of the Canadian Council for Animal Care. The 720 
primary model used for this study was depdc5 loss of function mutants. 721 
For generation of the depdc5 loss of function model, zebrafish optimized Cas9 mRNA was 722 
synthesized using the mMESSAGE mMACHINE SP6 kit (Ambion) and a pCS2-nCas9n 723 
template linearized with NotI. The following gRNA sequence targeting the 14th exon of depdc5 724 
was designed using the online tool CRISPRscan (PAM site is indicated in brackets): 5’-725 
TGAGGATCATGAGCAAT(CGG)-3’. Synthesis of gRNA and of Cas9 mRNA was performed 726 
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as described [42]. Briefly, a 52 nt oligo (sgRNA primer), containing the T7 promoter, the 20 nt 727 
of the specific sgRNA DNA binding sequence and a constant 15 nt tail for annealing, was used 728 
in combination with a 80 nt reverse oligo to add the sgRNA invariable 3′ end (tail primer). A 117 729 
bp PCR product was generated following these parameters: 3 minutes at 95°C, 30 cycles of 30 730 
seconds at 95°C, 30 seconds at 45°C and 30 seconds at 72°C, and a final step at 72°C for seven 731 
minutes. PCR products were purified using Qiaquick (Qiagen) columns and approximately 120–732 
150 ng of DNA were used as template for a T7 In vitro transcription (IVT) reaction 733 
(AmpliScribe-T7-Flash transcription kit from Epicentre). In vitro transcribed sgRNAs were 734 
DNAse treated and precipitated with Sodium Acetate/Ethanol. Cas9 mRNA was in vitro 735 
transcribed from DNA linearized by XbaI using the mMachine T3 kit (Ambio). In vitro 736 
transcribed mRNAs were purified by phenol-chloroform followed by isopropanol precipitation. 737 
Tubingen long fin (TL) wild-type embryos were collected for microinjection. A 1nL drop of a 738 
mix of 100 ng/μL of Cas9 mRNA and 30 ng/μL of gRNA was injected into one-cell stage 739 
embryos using a Picospritzer III pressure ejector. 740 
Genotyping of depdc5+/+ (wild type), +/- (heterozygous) and -/- (homozygous) animals 741 
was performed by high resolution melting analysis (HRM) using genomic DNA extracted by 742 
boiling the embryo/larva/clipped caudal fin in 50 mM NaOH for 10 minutes and then 743 
neutralizing it with 100 mM Tris HCl (pH 8). HRM primers were designed using the Universal 744 
Probe Library Assay Design Center (FP: 5’ ATGCGCTGTTTGGTGAGG 3’ and RP: 5’ 745 
TCCAGGAGTGGGTGTTTTTG 3’). All primer sets are available upon request. The PCR 746 
reactions were made with 5 μL of the Precision Melt Supermix for HRM analysis (Bio-Rad 747 
#172-5112), 0.5 μL of each primer (10 μM) and 2 μL of genomic DNA and water up to 10 μL. 748 
The PCR was performed in a LightCycler 480 Instrument II (Roche) using white 96 well plates. 749 
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Two-step Evagreen PCR reaction protocol was 95°C for 2 min, then 45 cycles of 95°C for 10 sec 750 
and 60°C for 30 sec, followed by 95°C for 30 sec, 60°C for 60 sec, the temperature was 751 
increased by 0.02°C/sec until 95°C for 10 sec, then cooling at 40°C. Curves were analyzed using 752 
the Roche LightCycler 480 software version 1.5.1.62.  753 
In order to eliminate any putative off-target mutations, F0 founder was outcrossed with Tubingen 754 
long fin wild-type fish for at least three generations before phenotyping the embryos. All 755 
experiments were performed on larvae, and sex of zebrafish is not yet determined at this stage. 756 
depdc5+/- fish were incrossed to obtain depdc5+/+, +/- and -/- from the same cross for 757 
experiments. depdc5+/- fish of different generations have been used to verify consistency of the 758 
phenotype.  759 
 760 
Method details 761 
In situ hybridization 762 
A specific probe for depdc5 corresponding to the 5’ part of the coding sequence and first exon 763 
(971bp amplified with the following primers: FP: 5’ TGACACAGAAAGTAGAGTTTGCAGG 764 
3’; RP: 5’ GTTCTCAGCATCTTTGGGAGC 3’) was cloned within the pCS2+ vector using 765 
TOPO TA cloning kit (Invitrogen). After sequencing, antisense probe was transcribed in vitro 766 
using SP6 RNA polymerase. Whole-mount in situ hybridization of zebrafish embryos was 767 
performed as described by Thisse et al., 2008 [43]. Stained embryos were kept in 80% glycerol 768 
and imaged. 769 
 770 
Western blotting 771 
Larvae were anaesthetized and collected at 8 dpf, following which lysates were rapidly prepared 772 
by homogenization in high salt lysis buffer containing 10 mM Tris HCl (pH 8), 20% glycerol, 773 
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0.4 M KCl, protease and phosphatase inhibitors. After a freeze-thaw cycle to ensure efficient 774 
homogenization, the lysates were centrifuged at 13,000 rpm for 20 minutes. The supernatant was 775 
collected, and protein concentration was estimated using Bradford assay (Biorad). Western 776 
blotting was performed using 30 g lysate per sample which were resolved on a 12% SDS-777 
polyacrylamide gel. After electrophoresis, proteins on the gel were electrotransferred onto 0.22 778 
micron nitrocellulose membrane. The membranes were blocked with 5% non-fat milk solution in 779 
1X phosphate buffered saline or with 5% bovine serum albumin (Sigma) in 1X Tris buffered 780 
saline for immunoblotting with anti--tubulin (#T6557; Millipore Sigma) or anti-total S6 (2217; 781 
Cell Signaling Technologies) and anti-phospho S6 (#2215; Cell Signaling Technologies) 782 
respectively. Detection was performed using goat anti-mouse and goat anti-rabbit antibodies 783 
respectively conjugated with horse radish peroxidase. Bands were visualized with ECL and 784 
imaged using ChemiDoc (Biorad).  785 
 786 
Non-invasive local field potential (LFP) recordings 787 
Non-invasive recordings reading the electric signal from the head of the larvae were performed 788 
based on a modified protocol [19]. The larva was immobilized in 2% low melting point agarose 789 
(Invitrogen). Recording electrode (soda lime glass, Hilgenberg, Germany) was pulled with a 790 
DMZ Universal Puller (Zeitz, Germany) to a diameter of approximately 20 microns and filled 791 
with artificial cerebrospinal fluid (ACSF, 124 mM, NaCl, 2 mM KCl, 2 mM MgSO4, 2 mM 792 
CaCl2, 1.25 mM KH2PO4, 26 mM NaHCO3 and 10 mM glucose). The differential signal between 793 
the recording electrode positioned on larva’s head above the optic tectum and the reference 794 
electrode was amplified 10,000 times by DAGAN 2400 amplifier (Minnesota, USA), band pass 795 
filtered at 0.3-300 Hz and digitized at 2 kHz via a PCI-6251 interface (National Instruments, 796 
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UK) with WinEDR (John Dempster, University of Strathclyde, UK). The duration of each 797 
recording was 10 minutes. Epileptiform events consisted of multispike bursts with amplitudes 798 
exceeding at least three times baseline and lasted for minimum 100 msec. Electrophysiological 799 
recordings were analysed using Clampfit 10.2 software (Molecular Devices, USA). 800 
 801 
Motor activity measurements 802 
20 hpf embryos were embedded in low melting agarose and their movements inside the chorion 803 
were recorded using a camera for 20 minutes during which time they were kept hydrated. The 804 
Danioscope software (Noldus) was then used to quantify the percentage of time the embryos 805 
were active, the number of bursts and burst duration. At later stages (>5dpf), larvae were 806 
transferred individually into a 96-well plate and activity was recorded over light-dark cycles 807 
using Basler GenIcam camera and DanioVision recording chamber (Noldus). Analysis was 808 
performed using the Ethovision XT 12 software (Noldus) to quantify the distance swam.  809 
 810 
Drug treatment  811 
Drugs were procured from Sigma-Aldrich and LC Laboratories and stock solutions were 812 
prepared (PTZ-300mM, GABA-100 mM, Muscimol-30 mM, Baclofen-15 mM, Vigabatrin-1M 813 
in water and rapamycin-500 M in DMSO). Embryos were treated from 8 hpf unless mentioned 814 
otherwise. The water was replaced everyday with fresh water containing final concentration of 815 
the drug, till the activity measurement or end of the survival curve whichever was later.  For PTZ 816 
assay, manually dechorionated 2 dpf embryos were placed in a 96-well plate and let 817 
accommodated for 20-30 minutes. PTZ from stock solution (300mM) was diluted to the final 818 
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concentration (3mM) directly in the wells and the embryos were tracked immediately during 20 819 
minutes using a Daniovision (Noldus). 820 
 821 
 Transcriptomic, differential expression and pathway analyses 822 
Three independent batches of 10 dpf depdc5+/+ and -/- larvae were dissected to extract the 823 
whole brain, by each of two experimenters, corresponding to experimental triplicates. Total RNA 824 
was extracted from these flash frozen brains using PicoPure RNA extraction kit (Thermo Fisher 825 
Scientific) following the manufacturer’s standard protocol. For each sample, RNA extraction 826 
was made from 5 whole brains. Absence of contamination was assessed by Nanodrop using 827 
260/280 and 260/230 ratios. Quality of total RNA was assessed with the BioAnalyzer Nano 828 
(Agilent) and all samples had a RIN above 9.  829 
Library preparation was performed using the Truseq RNA (Illumina). 13 PCR cycles were 830 
required to amplify cDNA libraries. Libraries were quantified by Nanodrop and BioAnalyzer. 831 
All libraries were diluted to 10 nM and normalized with the Miseq SR50 v2. Libraries were 832 
pooled to equimolar concentration and multiplexed by 6 samples per lane. Sequencing was 833 
performed with the Illumina Hiseq2000 using the SBS Reagent Kit v3 (100 cycles, paired-end) 834 
with 1.6 nM of the pooled library. Cluster density was targeted at around 800k clusters/mm2. 835 
Between 45 and 55 million reads were generated for each sample. Library preparation and 836 
sequencing was done at the genomics platform of the Institute for Research in Immunology and 837 
Cancer (University of Montreal). About 90% of high quality reads were mapped onto the zv9 838 
version of the zebrafish genome (ensemble release 77) using TopHat version 2.0.10.  839 
Differential gene expression analysis was assessed by DeSeq2 package using R software. Genes 840 
showing an absolute fold change >1.4 and adjusted p value <0.05 were considered to be 841 
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significantly differentially expressed. Pathway analysis was performed using DAVID 842 
bioinformatics resources [44]. The list of differentially expressed genes was uploaded onto 843 
DAVID analysis wizard and a list of all expressed genes found in our dataset was used as a 844 
background for gene enrichment analysis.  845 
 846 
qRT-PCR 847 
400 ng of RNA extracted as described above was used for reverse transcription to prepare cDNA 848 
with the Superscript VILO cDNA synthesis kit. The cDNA was diluted 1:10 and used for qPCR 849 
with SYBR Green I Master (Roche) on a LightCycler 480 instrument. ef1a was used as the 850 
reference gene for normalization. Primers were designed using the Roche Universal Library 851 
Design Center online tool: gabrg2_F: cattcgtgtcctctcgagttc, gabrg2_R: agctgcgcttccacttgtat; 852 
kcc2_F: tggagccatgtacatcttgg, kcc2_R: tggcagctgatggaacaat; gat3_F: tgaacagaacgtgcccatag, 853 
gat3_R: cgctataaacgctagaccagga; plxn2a_F: agagcaaaaaccatcccaaa, plxn2a_R: 854 
gcatcttctcagcgacagact; sema3b_R: caacatggaccagcaactga, sema3b_R: ccacttgcattcatctcgtc; 855 
efnb3b_F: ctacacagggcatgaaggtg, efnb3b_R: ggagatttggctggcaga; mt-cyb_F: 856 
tgacttattcggagcatcca, mt-cyb_R: tagtcctcgggcgatgtg; mt-co2_F: gaaattaatgacccccacgttac, mt-857 
co2_R: cgtagcttcagtaccattgatgtc; ef1a_F: gtggctggagacagcaaga, ef1a_R: agagatctgaccagggtggtt. 858 
 859 
Immunostaining 860 
depdc5+/+ and depdc5-/- embryos were anaesthetized in 0.2% tricaine, fixed with 4% 861 
paraformaldehyde, cryoprotected in 10% sucrose overnight, and embedded in 7.5% gelatin/10% 862 
sucrose solution prior to flash freezing in isopentane. Samples were stored at -80°C until use. 863 
Embryos were cut into 20-µm-thick sections on cryostat, mounted on superfrost slides, and 864 
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stored at −80°C. For gephyrin immunostaining, depdc5+/+ and depdc5-/- embryos were 865 
embedded in OCT and frozen in liquid nitrogen. Cryosections (20 µm) were fixed in 4% 866 
paraformaldehyde at room temperature for 10 min. After washing thrice with PBS, sections were 867 
treated with 0.25% trypsin in 1X PBS for 2 min at 25°C. Immunohistochemistry was performed 868 
as previously described [45]. Briefly, sections were blocked and permeabilized with 0.2% 869 
gelatin, 0.25% Triton X100 diluted in 1X PBS for 1 hour at room temperature and then incubated 870 
overnight at room temperature with anti-GAD65/67 (1:500, rabbit polyclonal, Ab11070, 871 
Abcam), anti-Neuroligin 2 (Nlgn2) (1:300, rabbit polyclonal, Ab 36602, Abcam), or anti-872 
gephyrin (1:100, rabbit polyclonal, ab185930, Abcam). After several washes, sections were 873 
incubated for 1 hour with the donkey anti-rabbit coupled to Alexa Fluor 488 (1:500, Jackson 874 
Laboratories, West Grove, PA). Sections were counterstained for 10 minutes with 0.1% DAPI 875 
(Sigma-Aldrich) before being mounted with Vectashield Mounting Medium (Vector). Sections 876 
were analysed using a Leica TCS SP8 confocal scanning system (Leica Microsystems). Eight-877 
bit-digital images were collected using a Leica 40x HCPL APO CS2 oil-immersion objective 878 
(numerical aperture 1.30). Full-slices were captured 60-65 z-stacks, with a z step of 0.3 µm. 879 
Images were processed with ImageJ software (National Institutes of Health, USA).   880 
For whole mount immunostaining, depdc5+/+ and depdc5-/- embryos were anaesthetized in 881 
0.2% tricaine, fixed in Dent’s fixative (80% methanol and 20% DMSO) overnight. After 882 
rehydrating gradually into PBS, the larvae were permeabilized for 7 minutes in cold acetone. 883 
Larvae were blocked and permeabilized with 2% normal goat serum, 2% BSA and 1% DMSO 884 
diluted in 1X PBS for 1 hour at room temperature and then incubated overnight at 40C with anti-885 
acetylated tubulin (1:500, mouse monoclonal, Abcam) or anti-phosphorylated histone H3 (1:500, 886 
rabbit polyclonal, Millipore). After several washes, sections were incubated for 2 hours with the 887 
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goat anti-rabbit or goat anti-mouse coupled to Alexa Fluor 488. After washing, the fluorescence 888 
was analyzed by confocal microscopy (Olympus BX61W1 equipped with a Quorum Technology 889 
spinning disk head connected to a Hamamatsu ORCA-ER camera). Images were analysed using 890 
Volocity software (Improvision).  891 
 892 
Cresyl violet staining 893 
depdc5+/+ and -/- embryos were anaesthetized in 0.2% tricaine, fixed with 10% 894 
paraformaldehyde, embedded in paraffin, and sectioned. After deparaffinization and 895 
rehydradation, slides were stained with 0.5% cresyl violet (Sigma; in 0.3% acetic acid). Sections 896 
were differentiated in 70% ethanol and dehydrated in 100% ethanol. After clearing in xylene, 897 
coverslips were mounted using Pertex mounting medium (HistoLab, Gothenburg, Sweden). The 898 
slices of embryos were photographed with a microscope Nikon Eclipse (E-200) equipped with a 899 
digital sight (Nikon). 900 
 901 
Morphological analysis 902 
3 dpf depdc5+/+ and -/- larvae were anaesthesized and dorsal and lateral images of the whole 903 
body were acquired using the same parameters for all larvae. Body length, eye size, head size 904 
and surface area were measured using the Danioscope software. Body length was measured from 905 
the anterior tip to the caudal peduncle. Eye size and brain surface area were measured by 906 
specifying the eye and brain boundaries.  907 
 908 
Quantification and statistical analysis 909 
Quantification of gephyrin-labelled puncta and GAD65/67-labelled neurofilaments 910 
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Apotome images from 20 μm sections labelled with anti-gephyrin were deconvoluted using 911 
AutoQuant X (version X3.1.1) and processed using Image J (version 1.51s). Z-stacks were 912 
manually contrasted to maximize synaptic puncta visibility and reduce background noise. Using 913 
a semi-automatic macro, they were segmented by thresholding after filtering only synaptic 914 
puncta with diameters varying from 0.15 to 2μm (macro written by Zsolt CSABA, INSERM 915 
UMR1141). For each image, the total number of gephyrin-positive synapse puncta was divided 916 
by the whole surface filled by these synapses to get the number of synapses per μm2. The ratios 917 
of a total number of images from three independent experiments (n (depdc5+/+) =9; n(depdc5-/-918 
) =19) were averaged to get the means and standard errors of the means (SEM) and assess 919 
statistical tests between the two samples’ groups. 920 
For Gad65/67 quantification, 20 μm sections labelled with anti-GAD65/67 were imaged at zoom 921 
6 using Leica HC PL APO CS 40X objective and processed using Bitplane Imaris (version 922 
9.0.2). MeasurementPro’s Filaments that detects automatically filament-like structures was used 923 
to outline and quantify the dendrites. Images from three independent experiments 924 
(n(depdc5+/+)=3 ; n(depdc5-/-)=3) were used to calculate the means and their standard errors 925 
(SEM) and assess statistical tests between the two groups. 926 
 927 
Quantification of morphological and locomotion parameters was performed using Danioscope 928 
and Ethovision softwares respectively (Noldus) (described above). All data acquisition and 929 
quantification was performed by experimenter blind to the genotype of the larva. There is no 930 
evident morphological difference between depdc5+/+ and -/- which might bias the experimenter.  931 
Details of biological and technical replicates, statistical test used and significance are mentioned 932 
in the corresponding figure legend. All experiments have been repeated thrice on an average 933 
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(represented by N) and the number of animals per genotype used in each experiment is 934 
represented by n. In most instances, unpaired Student’s t test was performed to estimate 935 
statistical significance. If p>0.05, not significant, p<0.05: *, p<0.01: **, p<0.001: *** and 936 
p<0.0001:****  937 
 938 
Data and software availability 939 
Complete list of significantly up- and downregulated genes (p<0.05) in depdc5-/- larval brains in 940 
comparison to depdc5+/+ brains is available in Table S1. Complete list of genes overlapping 941 
between the depdc5 and gabra1 datasets is available in Table S2. Table S3 has a list of common 942 
genes between depdc5 and gabra1 datasets classified according to function. Table S4 gives the 943 
complete list of genes overlapping between depdc5 and tsc2 datasets.  944 
 945 
 946 
 947 
Supplemental file information: 948 
 949 
 950 
Supplemental videos: 951 
 952 
Video S1: 3D GAD65/67-labelled neurofilaments in depdc5+/+ larval brains 953 
Reconstruction of 3D-images from fluorescent immunodetection of GAD65/67 accumulation 954 
(green) on cryostat sections of 6 dpf depdc5+/+ zebrafish embryos combined with DAPI 955 
staining were imaged using confocal microscopy. Subsequently, z-stacks of selected region were 956 
rendered into 3D volume using Imaris (Bitplane Inc.).  957 
Related to figure 4.  958 
 959 
Video S2: 3D GAD65/67-labelled neurofilaments in depdc5-/- larval brains 960 
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Reconstruction of 3D-images from fluorescent immunodetection of GAD65/67 accumulation 961 
(green) on cryostat sections of 6 dpf depdc5-/- zebrafish embryos combined with DAPI staining 962 
were imaged using confocal microscopy. Subsequently, z-stacks of selected region were 963 
rendered into 3D volume using Imaris (Bitplane Inc.).  964 
Related to figure 4.  965 
 966 
 967 
Supplemental tables: 968 
 S1 Table: Complete list of significantly up- and downregulated genes in 10 dpf depdc5-/- 969 
larval brains in comparison to depdc5+/+ brains. Description of the top 5 up- and 970 
downregulated genes is provided. Related to figure 3.  971 
 972 
Table S2: List of common dysregulated genes between depdc5 and gabra1 datasets with the 973 
fold change and pattern of deregulation. Related to figure 6. 974 
 975 
Table S3: Common genes between depdc5 and gabra1 datasets classified according to 976 
function. Related to figure 6. 977 
 978 
Table S4: List of common genes between depdc5 and tsc2 datasets. Related to figure 6. 979 
 980 
 981 
 982 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
GAD65/67 Abcam Cat#Ab11070 
Gephyrin Abcam Cat#Ab185930 
Neuroligin 2 Abcam Cat#Ab36602 
Gamma-Tubulin Millipore Sigma Cat#T6557 
Phospho histone H3 Millipore Cat#09-838 
Phospho ribosomal protein S6 Cell Signaling 
Technologies 
Cat#2215 
Ribosomal protein S6 Cell Signaling 
Technologies 
Cat#2217 
Acetylated tubulin Sigma Aldrich Cat#T7451 
Bacterial and Virus Strains  
None N/A N/A 
   
Biological Samples   
RNA extracted from 10 dpf larval brains of depdc5+/+, 
+/- and -/- 
This manuscript N/A 
   
Chemicals, Peptides, and Recombinant Proteins 
In situ probe Synthesized N/A 
Pentylenetetrazol Sigma Cat#P6500 
Cresyl violet Sigma Cat#190-M 
Rapamycin LC Laboratories Cat#R-5000 
GABA Sigma Cat#A2129 
Vigabatrin Sigma Cat#V8261 
Muscimol Sigma Cat#M1523 
Baclofen Sigma Cat#B5399 
Precision Melt Supermix for High resolution melting 
(HRM) analysis 
Biorad Cat#172-5112 
Critical Commercial Assays 
mMESSAGE mMACHINE SP6 kit Ambion Cat#AM1340 
TOPO TA cloning kit Invitrogen Cat#451641 
PicoPure RNA extraction kit Thermo Fisher 
Scientific 
Cat#KIT0204 
Superscript VILO cDNA synthesis kti Invitrogen Cat#11754050 
   
Deposited Data 
Tsc2 mutant zebrafish data [20] N/A 
Gabra1 mutant zebrafish data Samarut et al (related 
manuscript, 
unpublished) 
N/A 
Depdc5 mutant zebrafish data This manuscript  N/A 
   
   
Experimental Models: Cell Lines 
None N/A N/A 
Key Resource Table
    
Experimental Models: Organisms/Strains 
Depdc5 loss of function mutant zebrafish This manuscript N/A 
Tubingen long fin (TL) wild type zebrafish ZIRC ZIRC_ID: ZL86 
   
Oligonucleotides 
Depdc5 HRM primers: sequence in methods Sigma N/A 
Guide RNA targeting 14th exon of depdc5 (details of 
synthesis in methods) 
This manuscript N/A 
qPCR primers for depdc5, GABA-related, axon-
guidance related and metabolism-related genes: 
sequence in methods 
Sigma N/A 
   
Recombinant DNA 
Plasmid encoding Cas9: pCS2-nCas9n  [42] N/A 
   
Software and Algorithms 
Danioscope Noldus Version 1.1 
http://www.noldus.co
m/danioscope/more-
about-danioscope 
Ethovision XT Noldus XT12 
http://www.noldus.co
m/EthoVision-
XT/New 
LightCycler 480 Roche V1.5 
https://lifescience.roc
he.com/en_ca/produ
cts/lightcycler14301-
480-instrument-
ii.html 
Image J NIH V1.51 
https://imagej.nih.go
v/ij/download.html 
R The R project V3.5.0 
https://www.r-
project.org 
Volocity Improvision-Perkin 
Elmer 
V3 
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